Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.62 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.59 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.59 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.59 |
| ▸ | TERT | O14746 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | DTYMK | P23919 | 4/20 | 0.54 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.48 |
| ▸ | TYMS | P04818 | 1/20 | 0.48 |
| ▸ | TK1 | P04183 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29519934 | 1.00 | F2 (0.62) | F2P2RY2P2RY4P2RY6TERT | |
| SCHEMBL30211177 | 1.00 | F2 (0.62) | F2P2RY2P2RY4P2RY6TERT | |
| SCHEMBL29369996 | 1.00 | F2 (0.62) | F2P2RY2P2RY4P2RY6TERT | |
| SCHEMBL29357819 | 1.00 | F2 (0.62) | F2P2RY2P2RY4P2RY6TERT | |
| SCHEMBL30092339 | 1.00 | F2 (0.62) | F2P2RY2P2RY4P2RY6TERT | |
| SCHEMBL29372542 | 1.00 | F2 (0.62) | F2P2RY2P2RY4P2RY6TERT | |
| SCHEMBL31103632 | 0.96 | F2 (0.67) | F2P2RY2P2RY4P2RY6TERT | |
| SCHEMBL30055250 | 0.96 | F2 (0.67) | F2P2RY2P2RY4P2RY6TERT | |
| SCHEMBL29551345 | 0.96 | F2 (0.67) | F2P2RY2P2RY4P2RY6TERT | |
| SCHEMBL29552315 | 0.96 | F2 (0.67) | F2P2RY2P2RY4P2RY6TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007741-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINES | AKAGERA MEDICINES, INC. (US) | 2026-01-08 | — | — | US | disclosed |
| CN-120131934-A | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof | 辉瑞大药厂 | 2025-06-13 | — | — | CN | disclosed |
| CN-119303072-A | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | 辉瑞公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-112336854-B | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof | 辉瑞大药厂 | 2024-11-26 | — | — | CN | disclosed |
| CN-118510548-A | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | 辉瑞公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-110787290-B | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | 辉瑞公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-110859957-B | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | 辉瑞公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117729933-A | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | 辉瑞公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-116744965-A | Immunogenic compositions for pneumococcal vaccines | 辉瑞大药厂 | 2023-09-12 | — | — | CN | disclosed |
| EP-4166572-A1 | ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF | Rinat Neuroscience Corp. (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20220323558-A1 | CANCER VACCINES | PFIZER INC. (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3230319-B1 | ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF | RINAT NEUROSCIENCE CORP (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220249657-A1 | ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF | RINAT NEUROSCIENCE CORP. (US) | 2022-08-11 | — | — | US | disclosed |
| US-11338035-B2 | Anti-PD-1 antibodies and methods of use thereof | RINAT NEUROSCIENCE CORP. (US) | 2022-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007741-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINES | TLR9, TLR3, TLR8 | F2 3735/4885P2RY2 265/4885P2RY4 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.